Back to News
Market Impact: 0.25
Biotech Stocks On Investor Radar - BOLT +66%, LYCA +33%, LUCD, GMAB
Source: Nasdaq
Healthcare & BiotechM&A & RestructuringPrivate Markets & Venture
Shares of several biotech companies moved higher following corporate, financing and clinical developments. Bolt Biotherapeutics gained after announcing a reverse merger with Prana Therapies and a $120 million private placement; Lycia Therapeutics also surged, but the supplied article text ends before giving the context.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
BOLT0.65
More News
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
- OpenAI Trims Target Value & Volvo Cars Cuts 2,500 Jobs
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- Fintech platform OPay files for $336 million U.S. initial public offering
- Oncologists Cheer Melanoma Data
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30